NMP in myeloma

NMP在骨髓瘤中的应用

• 批准号: nhmrc : GNT1067516
• 负责人: A/Pr Jake Shortt
• 金额: $ 53.36万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/nmp-myeloma/1344939
• 关键词: NMP; myeloma

We have newly discovered that a simple molecule called NMP has the ability to control myeloma cells that have become resistant to other available treatments. NMP works by enhancing immune function and by killing myeloma cells directly by inhibiting survival signals. NMP is different from all other types of available myeloma treatments. We intend to test the safety and power of NMP in the treatment of myeloma by running a clinical trial of NMP in patients with relapsed myeloma.

我们新发现一种称为 NMP 的简单分子能够控制对其他可用治疗产生耐药性的骨髓瘤细胞。 NMP 的作用是增强免疫功能，并通过抑制生存信号直接杀死骨髓瘤细胞。 NMP 不同于所有其他类型的可用骨髓瘤治疗方法。我们打算通过在复发性骨髓瘤患者中进行 NMP 临床试验来测试 NMP 治疗骨髓瘤的安全性和功效。